CT and MRI in Inflammatory Bowel Disease
Karin Horsthuis, Amsterdam
On-demand video of the lecture from July 7, 2022
Duration: ca. 21:19 min
Symposium 228
Abdominal Imaging in Gastroenterology and Hepatology
Session II: Inflammatory Bowel Disease
Chairs: K. Gecse, Amsterdam; A. Koch, Rotterdam
©Falk Foundation e.V., Freiburg. All rights reserved.
Pregnancy outcomes among infants of mothers with inflammatory bowel disease (IBD) exposed to corticosteroids: According to a large prospective registry of pregnant IBD patients offspring of women with IBD exposed to corticosteroids during pregnancy is more likely to experience adverse perinatal outcomes including preterm birth, low birth weight and admission to neonatal intensive care units.
Autoimmune hepatitis type 1: Aminotransferases during treatment predict long-term survival: A recent Dutch study shows that low aspartate aminotransferase after 6, 12, 24 or 36 months of treatment is a good prognostic marker in autoimmune hepatitis type 1. In contrast, immunoglobulin G level during treatment was not associated with survival.
Repair of symptomatic umbilical hernias in patients with cirrhosis remains a high-risk intervention: In particular, patients with a Model of End-stage Liver Disease (MELD) score > 15 or hyponatremia have a poor prognosis. Emergency operations are associated with a high rate of decompensation and longer hospital stays. Placement of a transjugular intrahepatic portosystemic shunt (TIPS) may improve prognosis, however, further prospective studies need to confirm this finding.
Surveillance for hepatocellular carcinoma (HCC) in high-risk patients: No benefit of a 3-months interval:A recent Italian study confirms that a shortened HCC surveillance interval of 3 months compared to 6 months has no benefit regarding early diagnosis, feasibility of curative treatment, or survival.
Vonoprazan-based therapy for Helicobacter pylori infection: Triple therapies containing the potassium-competitive acid blocker vonoprazan were superior to proton-pump inhibitor-based triple therapy in clarithromycin-resistant strains and in the overall study population in a randomized phase 3 trial performed in the US and in Europe.
Treatment of obesity with tirzepatide: In a 72-week trial, injection of 5 mg, 10 mg or 15 mg of the glucagon-like peptide 1 receptor agonist tirzepatide once weekly provided substantial and sustained reductions in body weight in a randomized phase 3 trial.
Head-to-head comparison of ustekinumab and adalimumab in Crohn’s disease: Both ustekinumab and adalimumab monotherapies were highly effective in a phase 3b trial involving biologic-naive patients with moderately to severely active Crohn’s disease (SEAVUE), with no difference in the primary end point of clinical remission.
Endoscopic versus surgical step-up approach for infected necrotizing pancreatitis: Long-term follow-up of a randomized trial (TENSION) indicates that endoscopic therapy was not superior to a surgical approach in reducing death or major complications. However, endoscopically treated patients developed fewer pancreaticocutaneous fistulas and needed fewer reinterventions.
Event
Symposium 230
State-of-the-Art Management of IBD: Current Realities and Future Horizons
November 25 – 26, 2022, Frankfurt, Germany
Kap Europa, Osloer Str. 5, 60327 Frankfurt, Germany
Symposium 230
Time for the liver – chronobiology, aging, and current matters in hepatology
January 26 – 27, 2023, Bochum, Germany
Veranstaltungszentrum der RUB Bochum, Universitätsstr. 150, 44801 Bochum, Germany
Current Falk literature:
Severe Liver Diseases and Liver Transplantation
Author: K. Herzer
(29 pages)
U13e